Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Contineum Therapeutics (CTNM) Gains from Investment Securities (2023 - 2025)

Contineum Therapeutics has reported Gains from Investment Securities over the past 3 years, most recently at $2474.0 for Q2 2025.

  • Quarterly results put Gains from Investment Securities at $2474.0 for Q2 2025, up 122.49% from a year ago — trailing twelve months through Dec 2025 was $5.5 million (down 11.38% YoY), and the annual figure for FY2024 was $4.0 million, up 51.27%.
  • Gains from Investment Securities for Q2 2025 was $2474.0 at Contineum Therapeutics, down from $5.5 million in the prior quarter.
  • Over the last five years, Gains from Investment Securities for CTNM hit a ceiling of $5.5 million in Q4 2024 and a floor of -$11000.0 in Q2 2024.
  • Median Gains from Investment Securities over the past 3 years was $117000.0 (2024), compared with a mean of $1.1 million.
  • Biggest five-year swings in Gains from Investment Securities: surged 2440.0% in 2024 and later surged 122.49% in 2025.
  • Contineum Therapeutics' Gains from Investment Securities stood at $602000.0 in 2023, then soared by 815.78% to $5.5 million in 2024, then tumbled by 99.96% to $2474.0 in 2025.
  • The last three reported values for Gains from Investment Securities were $2474.0 (Q2 2025), $5.5 million (Q4 2024), and $1.5 million (Q3 2024) per Business Quant data.